Clorox (CLX) Acquires GOJO Industries for $2.25 Billion to Expand Health Brands
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 24 2026
0mins
Source: seekingalpha
- Acquisition Expansion: Clorox announced the acquisition of hand hygiene and skincare manufacturer GOJO Industries for $2.25 billion in cash, aiming to enhance its market position in health and hygiene brands, thereby increasing its competitiveness in the rapidly growing personal care market.
- Fintech Integration: Capital One Financial agreed to acquire fintech company Brex for $5.15 billion, which specializes in technology for credit cards, expenses, and rewards, with the expectation that this deal will enhance Capital One's capabilities in digital financial services and drive business growth.
- Industry Consolidation: Deutsche Boerse agreed to acquire Allfunds Group, a European fund distribution platform, for approximately EUR 5.3 billion ($6.2 billion) in a cash and stock deal, aiming to expand its market share in financial services and enhance competitiveness.
- Biotech Acquisition: GSK has agreed to acquire US-based biotech firm RAPT Therapeutics for $2.2 billion, which focuses on developing treatments for inflammatory and immunologic diseases, thereby strengthening GSK's product portfolio and market influence in the biopharmaceutical sector.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy OGN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on OGN
Wall Street analysts forecast OGN stock price to fall
5 Analyst Rating
0 Buy
1 Hold
4 Sell
Strong Sell
Current: 13.160
Low
5.00
Averages
8.50
High
12.00
Current: 13.160
Low
5.00
Averages
8.50
High
12.00
About OGN
Organon & Co. is a global healthcare company. The Company is engaged in developing and delivering health solutions through a portfolio of prescription therapies and medical devices within women's health, biosimilars and a franchise of established medicines across a range of therapeutic areas. It has a portfolio of approximately 70 medicines and products across a range of therapeutic areas. It has a portfolio of contraception and fertility brands, including Nexplanon, NuvaRing, and Follistim AQ. Its Biosimilars portfolio spans across immunology and oncology treatments. It also has a portfolio of established brands, including brands in cardiovascular, dermatology and non-opioid pain management. It sells these products through various channels, including drug wholesalers and retailers, hospitals, government agencies and managed health care providers, such as pharmacy benefit managers and other institutions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
EU Approves First Biosimilar POHERDY for HER2-positive Breast Cancer
- Market Authorization Milestone: Shanghai Henlius Biotech and Organon announced that the European Commission has granted marketing authorization for POHERDY® (pertuzumab), the first biosimilar approved for all indications, marking a significant advancement in treatment access for HER2-positive breast cancer patients, which is expected to greatly enhance patient care options.
- Expanded Clinical Applications: POHERDY is approved for use in combination with trastuzumab and docetaxel for adults with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy, further enriching treatment options and addressing urgent market needs for effective therapies.
- Data-Driven Approval: The approval is based on a comprehensive data package, including structural and functional analytical data, clinical pharmacokinetic data, and comparative clinical studies demonstrating that POHERDY is highly similar to the reference product in terms of safety and efficacy, thereby boosting market confidence.
- Global Commercialization Strategy: The exclusive commercialization agreement between Henlius and Organon covers several biosimilars globally, excluding China, indicating the company's intent to expand in international markets, which is expected to drive future revenue growth.
See More
Nokia Shares Rise Over 5% Following Analyst Upgrades
- Nokia Stock Surge: Nokia shares rose over 5% to an intraday high of $11.31, driven by price target increases from Morgan Stanley, JPMorgan, and Argus, reflecting strong market confidence in the surge of demand for its AI-related products.
- Earnings Beat Expectations: The company reported a 54% increase in operating profit for Q1 2026, surpassing consensus estimates, and raised its revenue and profit growth guidance for 2026, further solidifying its competitive position in the telecommunications sector.
- Organon Acquisition News: Organon shares increased by over 1% to $13.38 after Sun Pharmaceutical Industries from India agreed to acquire the company in an all-cash deal valued at $11.75 billion, indicating optimistic market sentiment regarding its future prospects.
- X-Energy Strong Performance: X-Energy's stock has continued to rise since its Nasdaq debut, reaching a high of $37.10, which is over 13% above its opening price of $30.11, reflecting growing investor confidence in nuclear energy as a long-term solution for energy needs.
See More
U.S. Stock Futures Mostly Lower as Earnings Reports Loom
- Mixed Market Performance: On Monday, major U.S. indices showed mixed results, with the S&P 500 closing at 7,173, having reached new highs before retreating, indicating cautious investor sentiment ahead of upcoming earnings reports.
- Rising Treasury Yields: Treasury yields increased across the board, with the 30-year bond yield at 4.94% and the 10-year note at 4.33%, reflecting market expectations for potential rate hikes amid rising oil prices and a strong dollar.
- Oil Price Surge: Brent crude oil prices rose by 2.74% to $108.20, while West Texas Intermediate increased by 2.15%, driven by ongoing geopolitical tensions in the Middle East, highlighting the impact of global events on energy markets.
- Increased Crypto Volatility: Bitcoin failed to break the $80,000 resistance level, closing at $76,140, as rising oil prices and geopolitical tensions led to profit-taking, underscoring the market's sensitivity to external factors affecting cryptocurrency valuations.
See More
ORGANON & CO: PIPER SANDLER UPGRADES TO NEUTRAL AND INCREASES TARGET PRICE TO $14 FROM $5
- Company Announcement: Organon and Co. has raised the price of its drug, Nulojix, from $5 to $14.
- Market Impact: This price increase is expected to enhance the company's revenue and market position.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Legal Investigation Launched: Halper Sadeh LLC is investigating Organon & Co. (NYSE: OGN) regarding its sale to Sun Pharmaceutical Industries Limited for $14.00 per share, which may infringe on shareholder rights.
- Shareholder Rights Protection: The firm is also scrutinizing XOMA Royalty Corporation (NASDAQ: XOMA)'s sale to Ligand Pharmaceuticals Incorporated for $39.00 per share, urging shareholders to understand their legal rights and options.
- RE/MAX Transaction Review: RE/MAX Holdings, Inc. (NYSE: RMAX) is set to sell to The Real Brokerage Inc. for either 5.152 shares or $13.80 in cash per share, with Halper Sadeh LLC warning shareholders about terms that may limit superior competing offers.
- Soleno Shareholder Rights: Soleno Therapeutics, Inc. (NASDAQ: SLNO) is selling to Neurocrine Biosciences for $53.00 per share in cash, and Halper Sadeh LLC encourages shareholders to learn about their legal rights and potential remedies.
See More
U.S. Stocks Decline Amid Geopolitical Tensions and Earnings Strength
- Geopolitical Tensions: Stalled peace negotiations between the U.S. and Iran have led to rising oil prices, raising fresh concerns about inflation and global economic growth, as investors balance strong corporate earnings against geopolitical uncertainties.
- Earnings Performance: Verizon (VZ) reported a better-than-expected Q1, while Domino's Pizza (DPZ) posted disappointing results and announced an additional $1 billion share repurchase program, highlighting the varied market reactions to different companies.
- Acquisition Activity: Shell (SHEL) agreed to acquire ARC Resources (AETUF) for C$32.80 per share, while China blocked Meta's (META) acquisition of AI startup Manus, reflecting the complexities of the global M&A landscape.
- Market Index Fluctuations: Near midday, the Dow was down 0.25%, the Nasdaq down 0.28%, and the S&P 500 down 0.14%, indicating the market's sensitive response to geopolitical tensions and economic data.
See More
EU Approves First Biosimilar POHERDY for HER2-positive Breast Cancer
- Market Authorization Milestone: Shanghai Henlius Biotech and Organon announced that the European Commission has granted marketing authorization for POHERDY® (pertuzumab), the first biosimilar approved for all indications, marking a significant advancement in treatment access for HER2-positive breast cancer patients, which is expected to greatly enhance patient care options.
- Expanded Clinical Applications: POHERDY is approved for use in combination with trastuzumab and docetaxel for adults with HER2-positive metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy, further enriching treatment options and addressing urgent market needs for effective therapies.
- Data-Driven Approval: The approval is based on a comprehensive data package, including structural and functional analytical data, clinical pharmacokinetic data, and comparative clinical studies demonstrating that POHERDY is highly similar to the reference product in terms of safety and efficacy, thereby boosting market confidence.
- Global Commercialization Strategy: The exclusive commercialization agreement between Henlius and Organon covers several biosimilars globally, excluding China, indicating the company's intent to expand in international markets, which is expected to drive future revenue growth.
See More
Nokia Shares Rise Over 5% Following Analyst Upgrades
- Nokia Stock Surge: Nokia shares rose over 5% to an intraday high of $11.31, driven by price target increases from Morgan Stanley, JPMorgan, and Argus, reflecting strong market confidence in the surge of demand for its AI-related products.
- Earnings Beat Expectations: The company reported a 54% increase in operating profit for Q1 2026, surpassing consensus estimates, and raised its revenue and profit growth guidance for 2026, further solidifying its competitive position in the telecommunications sector.
- Organon Acquisition News: Organon shares increased by over 1% to $13.38 after Sun Pharmaceutical Industries from India agreed to acquire the company in an all-cash deal valued at $11.75 billion, indicating optimistic market sentiment regarding its future prospects.
- X-Energy Strong Performance: X-Energy's stock has continued to rise since its Nasdaq debut, reaching a high of $37.10, which is over 13% above its opening price of $30.11, reflecting growing investor confidence in nuclear energy as a long-term solution for energy needs.
See More
U.S. Stock Futures Mostly Lower as Earnings Reports Loom
- Mixed Market Performance: On Monday, major U.S. indices showed mixed results, with the S&P 500 closing at 7,173, having reached new highs before retreating, indicating cautious investor sentiment ahead of upcoming earnings reports.
- Rising Treasury Yields: Treasury yields increased across the board, with the 30-year bond yield at 4.94% and the 10-year note at 4.33%, reflecting market expectations for potential rate hikes amid rising oil prices and a strong dollar.
- Oil Price Surge: Brent crude oil prices rose by 2.74% to $108.20, while West Texas Intermediate increased by 2.15%, driven by ongoing geopolitical tensions in the Middle East, highlighting the impact of global events on energy markets.
- Increased Crypto Volatility: Bitcoin failed to break the $80,000 resistance level, closing at $76,140, as rising oil prices and geopolitical tensions led to profit-taking, underscoring the market's sensitivity to external factors affecting cryptocurrency valuations.
See More
ORGANON & CO: PIPER SANDLER UPGRADES TO NEUTRAL AND INCREASES TARGET PRICE TO $14 FROM $5
- Company Announcement: Organon and Co. has raised the price of its drug, Nulojix, from $5 to $14.
- Market Impact: This price increase is expected to enhance the company's revenue and market position.
See More
Investor Rights Law Firm Investigates Multiple Companies
- Legal Investigation Launched: Halper Sadeh LLC is investigating Organon & Co. (NYSE: OGN) regarding its sale to Sun Pharmaceutical Industries Limited for $14.00 per share, which may infringe on shareholder rights.
- Shareholder Rights Protection: The firm is also scrutinizing XOMA Royalty Corporation (NASDAQ: XOMA)'s sale to Ligand Pharmaceuticals Incorporated for $39.00 per share, urging shareholders to understand their legal rights and options.
- RE/MAX Transaction Review: RE/MAX Holdings, Inc. (NYSE: RMAX) is set to sell to The Real Brokerage Inc. for either 5.152 shares or $13.80 in cash per share, with Halper Sadeh LLC warning shareholders about terms that may limit superior competing offers.
- Soleno Shareholder Rights: Soleno Therapeutics, Inc. (NASDAQ: SLNO) is selling to Neurocrine Biosciences for $53.00 per share in cash, and Halper Sadeh LLC encourages shareholders to learn about their legal rights and potential remedies.
See More
U.S. Stocks Decline Amid Geopolitical Tensions and Earnings Strength
- Geopolitical Tensions: Stalled peace negotiations between the U.S. and Iran have led to rising oil prices, raising fresh concerns about inflation and global economic growth, as investors balance strong corporate earnings against geopolitical uncertainties.
- Earnings Performance: Verizon (VZ) reported a better-than-expected Q1, while Domino's Pizza (DPZ) posted disappointing results and announced an additional $1 billion share repurchase program, highlighting the varied market reactions to different companies.
- Acquisition Activity: Shell (SHEL) agreed to acquire ARC Resources (AETUF) for C$32.80 per share, while China blocked Meta's (META) acquisition of AI startup Manus, reflecting the complexities of the global M&A landscape.
- Market Index Fluctuations: Near midday, the Dow was down 0.25%, the Nasdaq down 0.28%, and the S&P 500 down 0.14%, indicating the market's sensitive response to geopolitical tensions and economic data.
See More
